WO2005009410A2 - Pharmaceutical compositions having a swellable coating - Google Patents
Pharmaceutical compositions having a swellable coating Download PDFInfo
- Publication number
- WO2005009410A2 WO2005009410A2 PCT/US2004/022910 US2004022910W WO2005009410A2 WO 2005009410 A2 WO2005009410 A2 WO 2005009410A2 US 2004022910 W US2004022910 W US 2004022910W WO 2005009410 A2 WO2005009410 A2 WO 2005009410A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dosage form
- pharmaceutical dosage
- coating
- pharmaceutical
- core
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2873—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
Definitions
- controlled release formulations having drug-containing core and a controlled release hydrophobic coating of ethylcellulose, optionally containing a hydrophilic pore forming substance such as hydroxypropyl methylcellulose.
- the cores can have an intermediate "barrier" coating of a substance such as hydroxypropyl methylcellulose, which preferably does not affect the dissolution rate of the final product.
- oral formulations in which the unpleasant taste of a drug substance is masked, but in which the drug is immediately bioavailable upon exposure to acidic fluid in the stomach, are prepared by coating a drug-containing core particle with a mixture of a prolamine and a nonpolymeric plasticizer.
- the subject invention provides a pharmaceutical dosage form comprising a core that comprises a pharmaceutical active ingredient, and a swellable coating surrounding the core.
- the core comprises at least 50%, at least 60%, at least 70%, preferably at least 80%, preferably at least 82.5%, preferably at least 85%, preferably at least 87%, preferably at least 88%, preferably at least 89% of the total pharmaceutical composition.
- the core may also comprise at least 90%, at least 91 %, at least 92% or at least 93% of the total pharmaceutical composition.
- the terms "pharmaceutical active ingredient” "pharmaceutical active” and “active” are used interchangeably to refer to a component of a pharmaceutical dosage form that provides a therapeutic effect upon administration to a subject.
- the hydrocolloid can also be formed from a hydroxypropyl methylcellulose.
- the viscosity of a 2 weight percent aqueous solution of various hydroxypropyl methylcellulose products ranges from about 4,000 mPa-s to about 100,000 mPa-s.
- the hydroxypropyl methylcellulose is United States Pharmacopeia Substitution Type 2208, also called hypromellose 2208, with a viscosity of about 15,000 mPa-s, which is commercially available as Methocel K15M.
- these inks are normally air dried.
- Other pharmaceutically acceptable inks include those products sold as OpacodeTM and OpacodeTM WB, both of which contain pigments, titanium dioxide, and a solvent and are sold by Colorcon, West Point, Pennsylvania USA.
- Many other printing inks are known to those skilled in the art, and any of these will be useful for the dosage forms of the invention.
- the enteric-coated dosage forms can be further coated with a thin film. Frequently, the film will be colored to facilitate product identification and for esthetic purposes; in this instance, any desired printing of information will be done after the film coating has been applied.
- Many suitable film coating products are commercially available, including those sold by Colorcon, West Point, Pennsylvania USA using the OPADRY and OPAGLOS trademarks.
- Tablet cores were prepared by granulating a dry mix of pantoprazole sodium, mannitol, crospovidone and sodium carbonate with an aqueous solution of hydroxypropyl cellulose (Klucel LF) and sodium carbonate anhydrous. The granulates were dried using conventional drying techniques. The dried granules were then lubricated with crospovidone, talc and calcium stearate. The lubricated granules were compressed into cores. The cores were subcoated with a mixture of zein, Eudragit L 100-55, water, and isopropyl alcohol, and dried.
- Magnesium oxide was sifted through a 60 mesh sieve. Rabeprazole sodium, L-HPC, mannitol (SD 200) and the sifted magnesium oxide were sifted through a 40 mesh sieve. The materials were then mixed for 30 minutes in a Rapid mixer granulator. Sodium lauryl sulfate (SLS) was dissolved in purified water and hydroxypropylmethylcellulose (HPMC) was dissolved in warm purified water. The rabeprazole sodium mixture was mixed with the SLS and HPMC solutions. The wet mass was dried in a fluid bed drier and the dried granules were sifted through a 20 mesh sieve.
- SLS Sodium lauryl sulfate
- HPMC hydroxypropylmethylcellulose
- Esomeprazole magnesium trihydrate, magnesium oxide, Plasdone S-630, silicon dioxide, and mannitol were sieved and blended, then sodium stearyl fumarate was added and the mixture blended, and finally tablets were formed by direct compression of the mixture.
- Zein was dissolved in aqueous alcohol and coated onto the tablets. The coated tablets were then dried. Additional tablets were similarly prepared, further including either 7 mg or 10 mg of the disintegrant ingredient crospovidone in the core composition, with corresponding decreases in the amount of mannitol to maintain constant tablet weights.
- the tablets were tested for dissolution characteristics at pH 6.8, using the procedure of Example 10 (except that the acid contact step was omitted) and giving the following results.
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ544608A NZ544608A (en) | 2003-07-17 | 2004-07-16 | Pharmaceutical compositions having a swellable coating comprising prolamin |
EP04778421A EP1651193A2 (en) | 2003-07-17 | 2004-07-16 | Pharmaceutical compositions having a swellable coating |
BRPI0412697-1A BRPI0412697A (en) | 2003-07-17 | 2004-07-16 | pharmaceutical compositions having an expandable coating |
AU2004259226A AU2004259226B2 (en) | 2003-07-17 | 2004-07-16 | Pharmaceutical compositions having a swellable coating |
CA002532310A CA2532310A1 (en) | 2003-07-17 | 2004-07-16 | Pharmaceutical compositions having a swellable coating |
JP2006520372A JP2007524646A (en) | 2003-07-17 | 2004-07-16 | Pharmaceutical composition having a swellable coating |
MXPA06000577A MXPA06000577A (en) | 2003-07-17 | 2004-07-16 | Pharmaceutical compositions having a swellable coating. |
IL173053A IL173053A0 (en) | 2003-07-17 | 2006-01-10 | Pharmaceutical compositions having a swellable coating |
HR20060016A HRP20060016A2 (en) | 2003-07-17 | 2006-01-12 | Pharmaceutical compositions having a swellable coating |
NO20060786A NO20060786L (en) | 2003-07-17 | 2006-02-17 | Pharmaceutical preparations with swelling coating |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN580CH2003 | 2003-07-17 | ||
IN580/CHE/03 | 2003-07-17 | ||
IN1064/CHE/03 | 2003-12-30 | ||
IN1064CH2003 | 2003-12-30 | ||
US56370704P | 2004-04-20 | 2004-04-20 | |
US60/563,707 | 2004-04-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005009410A2 true WO2005009410A2 (en) | 2005-02-03 |
WO2005009410A3 WO2005009410A3 (en) | 2005-05-19 |
Family
ID=34108415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/022910 WO2005009410A2 (en) | 2003-07-17 | 2004-07-16 | Pharmaceutical compositions having a swellable coating |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1651193A2 (en) |
JP (1) | JP2007524646A (en) |
KR (1) | KR20060065632A (en) |
AU (1) | AU2004259226B2 (en) |
BR (1) | BRPI0412697A (en) |
CA (1) | CA2532310A1 (en) |
HR (1) | HRP20060016A2 (en) |
IL (1) | IL173053A0 (en) |
MX (1) | MXPA06000577A (en) |
NO (1) | NO20060786L (en) |
NZ (1) | NZ544608A (en) |
WO (1) | WO2005009410A2 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1681052A1 (en) * | 2005-01-18 | 2006-07-19 | Dr. Reddy's Laboratories Ltd. | Solid pharmaceutical dosage forms for reducing the bioavailability food effect |
WO2006105798A2 (en) * | 2005-07-11 | 2006-10-12 | Nycomed Danmark Aps | Benzimidazole formulation |
WO2007029124A2 (en) * | 2005-05-13 | 2007-03-15 | Combino Pharm, S.L. | Formulations containing pantoprazole free acid and its salts |
WO2007080601A1 (en) * | 2006-01-16 | 2007-07-19 | Jubilant Organosys Limited | Stable pharmaceutical formulation of an acid labile compound and process for preparing the same |
JP2008520633A (en) * | 2004-11-24 | 2008-06-19 | フラメル・テクノロジー | Oral medicament in the form of a multi-microcapsule for modifying the release of at least one active ingredient |
WO2012001705A3 (en) * | 2010-06-29 | 2012-04-12 | Cadila Healthcare Limited | Pharmaceutical compositions of (r)-lansoprazole |
US9241910B2 (en) | 2008-03-11 | 2016-01-26 | Takeda Pharmaceutical Company Limited | Orally-disintegrating solid preparation |
EP2950790A4 (en) * | 2012-08-09 | 2018-04-25 | Dynamis Therapeutics, Inc. | Methods for maintaining or improving health, well-being and/or a physiological function in a subject |
EP3488845A4 (en) * | 2016-07-25 | 2020-04-08 | Hanmi Pharm. Co., Ltd. | Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof |
EP3513784A4 (en) * | 2016-10-28 | 2020-06-03 | Hanmi Pharm. Co., Ltd. | Esomeprazole-containing complex capsule and preparation method therefor |
CN111728124A (en) * | 2020-07-08 | 2020-10-02 | 江苏宏远药业有限公司 | Food-grade white pigment with high safety |
EP3648745A4 (en) * | 2017-09-28 | 2021-05-12 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition including multi-unit spheroidal tablet containing esomeprazole and spheroidal pharmaceutically acceptable salt thereof, and method of preparing the pharmaceutical composition |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2319504A1 (en) * | 2009-11-07 | 2011-05-11 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical solid dosage form |
JP6856326B2 (en) * | 2016-07-15 | 2021-04-07 | 富士化学工業株式会社 | Intestinal release particle composition |
JP6336651B1 (en) * | 2016-12-15 | 2018-06-06 | 大原薬品工業株式会社 | Tablets containing esomeprazole salts with improved chemical stability |
JP7026510B2 (en) * | 2018-01-11 | 2022-02-28 | 株式会社Screenホールディングス | Printed matter, readers, reading methods, printing methods, and printing devices |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US341338A (en) * | 1886-05-04 | Blind | ||
DD273197A5 (en) * | 1986-04-30 | 1989-11-08 | �����@������������������k�� | PROCESS FOR PREPARING AN ORAL PHARMACEUTICAL PREPARATION CONTAINING OMEPRAZOLE |
US5882715A (en) * | 1995-06-20 | 1999-03-16 | Pharma-Vinci A/S | Method of preparing an oral preparation provided on the outer side with an enteric coating, as well as an oral preparation obtained by the method |
US5997903A (en) * | 1991-06-17 | 1999-12-07 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Oral-administration forms of a medicament containing pantoprazol |
EP1092434A1 (en) * | 1995-09-21 | 2001-04-18 | Pharma Pass LLC | Novel composition containing lansoprazole and process for its preparation |
US6479075B1 (en) * | 1997-10-06 | 2002-11-12 | Isa Odidi | Pharmaceutical formulations for acid labile substances |
US6500459B1 (en) * | 1999-07-21 | 2002-12-31 | Harinderpal Chhabra | Controlled onset and sustained release dosage forms and the preparation thereof |
US6635206B1 (en) * | 2000-05-03 | 2003-10-21 | The Board Of Trustees Of The University Of Illinois | Method of manufacturing improved corn zein resin films, sheets, and articles |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6368628B1 (en) * | 2000-05-26 | 2002-04-09 | Pharma Pass Llc | Sustained release pharmaceutical composition free of food effect |
PE20050150A1 (en) * | 2003-05-08 | 2005-03-22 | Altana Pharma Ag | A DOSAGE FORM CONTAINING (S) -PANTOPRAZOLE AS AN ACTIVE INGREDIENT |
-
2004
- 2004-07-16 BR BRPI0412697-1A patent/BRPI0412697A/en not_active IP Right Cessation
- 2004-07-16 WO PCT/US2004/022910 patent/WO2005009410A2/en active Application Filing
- 2004-07-16 KR KR1020067001095A patent/KR20060065632A/en not_active Application Discontinuation
- 2004-07-16 JP JP2006520372A patent/JP2007524646A/en not_active Withdrawn
- 2004-07-16 AU AU2004259226A patent/AU2004259226B2/en not_active Ceased
- 2004-07-16 EP EP04778421A patent/EP1651193A2/en not_active Withdrawn
- 2004-07-16 MX MXPA06000577A patent/MXPA06000577A/en unknown
- 2004-07-16 CA CA002532310A patent/CA2532310A1/en not_active Abandoned
- 2004-07-16 NZ NZ544608A patent/NZ544608A/en unknown
-
2006
- 2006-01-10 IL IL173053A patent/IL173053A0/en unknown
- 2006-01-12 HR HR20060016A patent/HRP20060016A2/en not_active Application Discontinuation
- 2006-02-17 NO NO20060786A patent/NO20060786L/en not_active Application Discontinuation
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US341338A (en) * | 1886-05-04 | Blind | ||
DD273197A5 (en) * | 1986-04-30 | 1989-11-08 | �����@������������������k�� | PROCESS FOR PREPARING AN ORAL PHARMACEUTICAL PREPARATION CONTAINING OMEPRAZOLE |
US5997903A (en) * | 1991-06-17 | 1999-12-07 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Oral-administration forms of a medicament containing pantoprazol |
US5882715A (en) * | 1995-06-20 | 1999-03-16 | Pharma-Vinci A/S | Method of preparing an oral preparation provided on the outer side with an enteric coating, as well as an oral preparation obtained by the method |
EP1092434A1 (en) * | 1995-09-21 | 2001-04-18 | Pharma Pass LLC | Novel composition containing lansoprazole and process for its preparation |
EP1308159A1 (en) * | 1995-09-21 | 2003-05-07 | Pharma Pass II LLC | Pharmaceutical composition containing an acid-labile omeprazole and process for its preparation |
US6479075B1 (en) * | 1997-10-06 | 2002-11-12 | Isa Odidi | Pharmaceutical formulations for acid labile substances |
US6500459B1 (en) * | 1999-07-21 | 2002-12-31 | Harinderpal Chhabra | Controlled onset and sustained release dosage forms and the preparation thereof |
US6635206B1 (en) * | 2000-05-03 | 2003-10-21 | The Board Of Trustees Of The University Of Illinois | Method of manufacturing improved corn zein resin films, sheets, and articles |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008520633A (en) * | 2004-11-24 | 2008-06-19 | フラメル・テクノロジー | Oral medicament in the form of a multi-microcapsule for modifying the release of at least one active ingredient |
EP1681052A1 (en) * | 2005-01-18 | 2006-07-19 | Dr. Reddy's Laboratories Ltd. | Solid pharmaceutical dosage forms for reducing the bioavailability food effect |
WO2007029124A2 (en) * | 2005-05-13 | 2007-03-15 | Combino Pharm, S.L. | Formulations containing pantoprazole free acid and its salts |
WO2007029124A3 (en) * | 2005-05-13 | 2007-07-26 | Combino Pharm Sl | Formulations containing pantoprazole free acid and its salts |
WO2006105798A2 (en) * | 2005-07-11 | 2006-10-12 | Nycomed Danmark Aps | Benzimidazole formulation |
WO2006105798A3 (en) * | 2005-07-11 | 2006-12-07 | Nycomed Danmark Aps | Benzimidazole formulation |
EA015535B1 (en) * | 2005-07-11 | 2011-08-30 | Никомед Данмарк Апс | Benzimidazole formulation |
AU2006230974B2 (en) * | 2005-07-11 | 2011-09-29 | Takeda Pharma A/S | Benzimidazole formulation |
AU2006230974C1 (en) * | 2005-07-11 | 2012-02-02 | Takeda Pharma A/S | Benzimidazole formulation |
WO2007080601A1 (en) * | 2006-01-16 | 2007-07-19 | Jubilant Organosys Limited | Stable pharmaceutical formulation of an acid labile compound and process for preparing the same |
US8865212B2 (en) | 2006-01-16 | 2014-10-21 | Jubilant Generics Limited | Stable pharmaceutical formulation of an acid labile compound and process for preparing the same |
US9241910B2 (en) | 2008-03-11 | 2016-01-26 | Takeda Pharmaceutical Company Limited | Orally-disintegrating solid preparation |
WO2012001705A3 (en) * | 2010-06-29 | 2012-04-12 | Cadila Healthcare Limited | Pharmaceutical compositions of (r)-lansoprazole |
EP2950790A4 (en) * | 2012-08-09 | 2018-04-25 | Dynamis Therapeutics, Inc. | Methods for maintaining or improving health, well-being and/or a physiological function in a subject |
US9974757B2 (en) | 2012-08-09 | 2018-05-22 | Dynamics Therapeutics, Inc. | Methods for maintaining or improved health, well-being and/or a physiological function in a subject |
EP3488845A4 (en) * | 2016-07-25 | 2020-04-08 | Hanmi Pharm. Co., Ltd. | Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof |
US10946003B2 (en) | 2016-07-25 | 2021-03-16 | Hanmi Pharm. Co., Ltd. | Formulation having improved pH-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof |
EP3513784A4 (en) * | 2016-10-28 | 2020-06-03 | Hanmi Pharm. Co., Ltd. | Esomeprazole-containing complex capsule and preparation method therefor |
US11052048B2 (en) | 2016-10-28 | 2021-07-06 | Hanmi Pharm. Co., Ltd. | Esomeprazole-containing complex capsule and preparation method therefor |
EP3648745A4 (en) * | 2017-09-28 | 2021-05-12 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition including multi-unit spheroidal tablet containing esomeprazole and spheroidal pharmaceutically acceptable salt thereof, and method of preparing the pharmaceutical composition |
CN111728124A (en) * | 2020-07-08 | 2020-10-02 | 江苏宏远药业有限公司 | Food-grade white pigment with high safety |
Also Published As
Publication number | Publication date |
---|---|
NO20060786L (en) | 2006-04-10 |
AU2004259226B2 (en) | 2009-09-24 |
HRP20060016A2 (en) | 2006-02-28 |
IL173053A0 (en) | 2006-06-11 |
CA2532310A1 (en) | 2005-02-03 |
BRPI0412697A (en) | 2006-10-03 |
NZ544608A (en) | 2008-07-31 |
AU2004259226A1 (en) | 2005-02-03 |
JP2007524646A (en) | 2007-08-30 |
EP1651193A2 (en) | 2006-05-03 |
KR20060065632A (en) | 2006-06-14 |
MXPA06000577A (en) | 2006-07-03 |
WO2005009410A3 (en) | 2005-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050042277A1 (en) | Pharmaceutical compositions having a swellable coating | |
US20050147663A1 (en) | Method of treatment for improved bioavailability | |
HRP20060016A2 (en) | Pharmaceutical compositions having a swellable coating | |
KR100535954B1 (en) | Enteric coated pharmaceutical tablet and method of manufacturing | |
EP2026768B1 (en) | Multiple unit pharmaceutical formulation | |
RU2376983C2 (en) | Gastral retentive compositions and its production methods | |
AU2006284053B2 (en) | Pharmaceutical compositions comprising a pH-dependent drug, a pH modifier and a retarding agent | |
IE912644A1 (en) | Sustained release formulations | |
JP2009523784A (en) | Stable pharmaceutical preparation of acid labile compound and method for producing the same | |
AU2006284133A1 (en) | Solid pharmaceutical composition comprising 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine and a pH modifier | |
JP4540092B2 (en) | Pharmaceutical composition containing bioactive compound unstable to acid and process for producing the same | |
US20120231074A1 (en) | Pharmaceutical solid dosage form | |
EP2533766B1 (en) | Pharmaceutical mini-tablets for sustained release of flecainide acetate | |
WO2004098573A1 (en) | An improved and stable pharmaceutical composition containing substituted benzimidazoles and a process for its preparation | |
ZA200600432B (en) | Pharmaceutical compositions having a swellable coating | |
EP0978275A1 (en) | Solid pharmaceutical dosage form with controlled drug release | |
Naiserová et al. | perorálních tablet | |
WO2006136927A1 (en) | Extended release formulations comprising venlafaxine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480022908.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004778421 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2532310 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 544608 Country of ref document: NZ Ref document number: 2004259226 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20060016A Country of ref document: HR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/000577 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006/00432 Country of ref document: ZA Ref document number: 190/CHENP/2006 Country of ref document: IN Ref document number: 2006520372 Country of ref document: JP Ref document number: 200600432 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067001095 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2004259226 Country of ref document: AU Date of ref document: 20040716 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004259226 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006101082 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004778421 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067001095 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0412697 Country of ref document: BR |